Oxytocin receptor single nucleotide polymorphism predicts atony-related postpartum hemorrhage
Background Postpartum hemorrhage remains a key contributor to overall maternal morbidity in the United States. Current clinical assessment methods used to predict postpartum hemorrhage are unable to prospectively identify about 40% of hemorrhage cases. Oxytocin is a first-line pharmaceutical for pre...
Gespeichert in:
| Veröffentlicht in: | BMC pregnancy and childbirth Jg. 22; H. 1; S. 884 - 14 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
London
BioMed Central
29.11.2022
Springer Nature B.V BMC |
| Schlagworte: | |
| ISSN: | 1471-2393, 1471-2393 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Background
Postpartum hemorrhage remains a key contributor to overall maternal morbidity in the United States. Current clinical assessment methods used to predict postpartum hemorrhage are unable to prospectively identify about 40% of hemorrhage cases. Oxytocin is a first-line pharmaceutical for preventing and treating postpartum hemorrhage, which acts through oxytocin receptors on uterine myocytes. Existing research indicates that oxytocin function is subject to variation, influenced in part by differences in the DNA sequence within the oxytocin receptor gene. One variant, rs53576, has been shown to be associated with variable responses to exogenous oxytocin when administered during psychological research studies. How this variant may influence myometrial oxytocin response in the setting of third stage labor has not been studied. We tested for differences in the frequency of the oxytocin receptor genotype at rs53576 in relationship to the severity of blood loss among a sample of individuals who experienced vaginal birth.
Methods
A case–control prospective design was used to enroll 119 postpartum participants who underwent vaginal birth who were at least 37 weeks of gestation. Cases were defined by either a 1000 mL or greater blood loss or instances of heavier bleeding where parturients were given additional uterotonic treatment due to uterine atony. Controls were matched to cases on primiparity and labor induction status. Genotype was measured from a maternal blood sample obtained during the 2
nd
postpartum month from 95 participants. Statistical analysis included bivariate tests and generalized linear and Poisson regression modeling.
Results
The distribution of the genotype across the sample of 95 participants was 40% GG (
n
= 38), 50.5% AG (
n
= 48) and 9.5% AA (
n
= 9). Blood loss of 1000 mL or greater occurred at a rate of 7.9% for GG, 12.5% for AG and 55.6% for AA participants (
p
= 0.005). Multivariable models demonstrated A-carriers (versus GG) had 275.2 mL higher blood loss (95% CI 96.9–453.4,
p
< 0.01) controlling for parity, intrapartum oxytocin, self-reported ancestry, active management of third stage or genital tract lacerations. Furthermore, A-carrier individuals had a 79% higher risk for needing at least one second-line treatment (RR = 1.79, 95% CI = 1.08–2.95) controlling for covariates. Interaction models revealed that A-carriers who required no oxytocin for labor stimulation experienced 371.4 mL greater blood loss (95% CI 196.6–546.2 mL).
Conclusions
We provide evidence of a risk allele in the oxytocin receptor gene that may be involved in the development of postpartum hemorrhage among participants undergoing vaginal birth, particularly among those with fewer risk factors. The findings, if reproducible, could be useful in studying pharmacogenomic strategies for predicting, preventing or treating postpartum hemorrhage. |
|---|---|
| AbstractList | Background Postpartum hemorrhage remains a key contributor to overall maternal morbidity in the United States. Current clinical assessment methods used to predict postpartum hemorrhage are unable to prospectively identify about 40% of hemorrhage cases. Oxytocin is a first-line pharmaceutical for preventing and treating postpartum hemorrhage, which acts through oxytocin receptors on uterine myocytes. Existing research indicates that oxytocin function is subject to variation, influenced in part by differences in the DNA sequence within the oxytocin receptor gene. One variant, rs53576, has been shown to be associated with variable responses to exogenous oxytocin when administered during psychological research studies. How this variant may influence myometrial oxytocin response in the setting of third stage labor has not been studied. We tested for differences in the frequency of the oxytocin receptor genotype at rs53576 in relationship to the severity of blood loss among a sample of individuals who experienced vaginal birth. Methods A case–control prospective design was used to enroll 119 postpartum participants who underwent vaginal birth who were at least 37 weeks of gestation. Cases were defined by either a 1000 mL or greater blood loss or instances of heavier bleeding where parturients were given additional uterotonic treatment due to uterine atony. Controls were matched to cases on primiparity and labor induction status. Genotype was measured from a maternal blood sample obtained during the 2nd postpartum month from 95 participants. Statistical analysis included bivariate tests and generalized linear and Poisson regression modeling. Results The distribution of the genotype across the sample of 95 participants was 40% GG (n = 38), 50.5% AG (n = 48) and 9.5% AA (n = 9). Blood loss of 1000 mL or greater occurred at a rate of 7.9% for GG, 12.5% for AG and 55.6% for AA participants (p = 0.005). Multivariable models demonstrated A-carriers (versus GG) had 275.2 mL higher blood loss (95% CI 96.9–453.4, p < 0.01) controlling for parity, intrapartum oxytocin, self-reported ancestry, active management of third stage or genital tract lacerations. Furthermore, A-carrier individuals had a 79% higher risk for needing at least one second-line treatment (RR = 1.79, 95% CI = 1.08–2.95) controlling for covariates. Interaction models revealed that A-carriers who required no oxytocin for labor stimulation experienced 371.4 mL greater blood loss (95% CI 196.6–546.2 mL). Conclusions We provide evidence of a risk allele in the oxytocin receptor gene that may be involved in the development of postpartum hemorrhage among participants undergoing vaginal birth, particularly among those with fewer risk factors. The findings, if reproducible, could be useful in studying pharmacogenomic strategies for predicting, preventing or treating postpartum hemorrhage. Postpartum hemorrhage remains a key contributor to overall maternal morbidity in the United States. Current clinical assessment methods used to predict postpartum hemorrhage are unable to prospectively identify about 40% of hemorrhage cases. Oxytocin is a first-line pharmaceutical for preventing and treating postpartum hemorrhage, which acts through oxytocin receptors on uterine myocytes. Existing research indicates that oxytocin function is subject to variation, influenced in part by differences in the DNA sequence within the oxytocin receptor gene. One variant, rs53576, has been shown to be associated with variable responses to exogenous oxytocin when administered during psychological research studies. How this variant may influence myometrial oxytocin response in the setting of third stage labor has not been studied. We tested for differences in the frequency of the oxytocin receptor genotype at rs53576 in relationship to the severity of blood loss among a sample of individuals who experienced vaginal birth.BACKGROUNDPostpartum hemorrhage remains a key contributor to overall maternal morbidity in the United States. Current clinical assessment methods used to predict postpartum hemorrhage are unable to prospectively identify about 40% of hemorrhage cases. Oxytocin is a first-line pharmaceutical for preventing and treating postpartum hemorrhage, which acts through oxytocin receptors on uterine myocytes. Existing research indicates that oxytocin function is subject to variation, influenced in part by differences in the DNA sequence within the oxytocin receptor gene. One variant, rs53576, has been shown to be associated with variable responses to exogenous oxytocin when administered during psychological research studies. How this variant may influence myometrial oxytocin response in the setting of third stage labor has not been studied. We tested for differences in the frequency of the oxytocin receptor genotype at rs53576 in relationship to the severity of blood loss among a sample of individuals who experienced vaginal birth.A case-control prospective design was used to enroll 119 postpartum participants who underwent vaginal birth who were at least 37 weeks of gestation. Cases were defined by either a 1000 mL or greater blood loss or instances of heavier bleeding where parturients were given additional uterotonic treatment due to uterine atony. Controls were matched to cases on primiparity and labor induction status. Genotype was measured from a maternal blood sample obtained during the 2nd postpartum month from 95 participants. Statistical analysis included bivariate tests and generalized linear and Poisson regression modeling.METHODSA case-control prospective design was used to enroll 119 postpartum participants who underwent vaginal birth who were at least 37 weeks of gestation. Cases were defined by either a 1000 mL or greater blood loss or instances of heavier bleeding where parturients were given additional uterotonic treatment due to uterine atony. Controls were matched to cases on primiparity and labor induction status. Genotype was measured from a maternal blood sample obtained during the 2nd postpartum month from 95 participants. Statistical analysis included bivariate tests and generalized linear and Poisson regression modeling.The distribution of the genotype across the sample of 95 participants was 40% GG (n = 38), 50.5% AG (n = 48) and 9.5% AA (n = 9). Blood loss of 1000 mL or greater occurred at a rate of 7.9% for GG, 12.5% for AG and 55.6% for AA participants (p = 0.005). Multivariable models demonstrated A-carriers (versus GG) had 275.2 mL higher blood loss (95% CI 96.9-453.4, p < 0.01) controlling for parity, intrapartum oxytocin, self-reported ancestry, active management of third stage or genital tract lacerations. Furthermore, A-carrier individuals had a 79% higher risk for needing at least one second-line treatment (RR = 1.79, 95% CI = 1.08-2.95) controlling for covariates. Interaction models revealed that A-carriers who required no oxytocin for labor stimulation experienced 371.4 mL greater blood loss (95% CI 196.6-546.2 mL).RESULTSThe distribution of the genotype across the sample of 95 participants was 40% GG (n = 38), 50.5% AG (n = 48) and 9.5% AA (n = 9). Blood loss of 1000 mL or greater occurred at a rate of 7.9% for GG, 12.5% for AG and 55.6% for AA participants (p = 0.005). Multivariable models demonstrated A-carriers (versus GG) had 275.2 mL higher blood loss (95% CI 96.9-453.4, p < 0.01) controlling for parity, intrapartum oxytocin, self-reported ancestry, active management of third stage or genital tract lacerations. Furthermore, A-carrier individuals had a 79% higher risk for needing at least one second-line treatment (RR = 1.79, 95% CI = 1.08-2.95) controlling for covariates. Interaction models revealed that A-carriers who required no oxytocin for labor stimulation experienced 371.4 mL greater blood loss (95% CI 196.6-546.2 mL).We provide evidence of a risk allele in the oxytocin receptor gene that may be involved in the development of postpartum hemorrhage among participants undergoing vaginal birth, particularly among those with fewer risk factors. The findings, if reproducible, could be useful in studying pharmacogenomic strategies for predicting, preventing or treating postpartum hemorrhage.CONCLUSIONSWe provide evidence of a risk allele in the oxytocin receptor gene that may be involved in the development of postpartum hemorrhage among participants undergoing vaginal birth, particularly among those with fewer risk factors. The findings, if reproducible, could be useful in studying pharmacogenomic strategies for predicting, preventing or treating postpartum hemorrhage. Postpartum hemorrhage remains a key contributor to overall maternal morbidity in the United States. Current clinical assessment methods used to predict postpartum hemorrhage are unable to prospectively identify about 40% of hemorrhage cases. Oxytocin is a first-line pharmaceutical for preventing and treating postpartum hemorrhage, which acts through oxytocin receptors on uterine myocytes. Existing research indicates that oxytocin function is subject to variation, influenced in part by differences in the DNA sequence within the oxytocin receptor gene. One variant, rs53576, has been shown to be associated with variable responses to exogenous oxytocin when administered during psychological research studies. How this variant may influence myometrial oxytocin response in the setting of third stage labor has not been studied. We tested for differences in the frequency of the oxytocin receptor genotype at rs53576 in relationship to the severity of blood loss among a sample of individuals who experienced vaginal birth. A case-control prospective design was used to enroll 119 postpartum participants who underwent vaginal birth who were at least 37 weeks of gestation. Cases were defined by either a 1000 mL or greater blood loss or instances of heavier bleeding where parturients were given additional uterotonic treatment due to uterine atony. Controls were matched to cases on primiparity and labor induction status. Genotype was measured from a maternal blood sample obtained during the 2 postpartum month from 95 participants. Statistical analysis included bivariate tests and generalized linear and Poisson regression modeling. The distribution of the genotype across the sample of 95 participants was 40% GG (n = 38), 50.5% AG (n = 48) and 9.5% AA (n = 9). Blood loss of 1000 mL or greater occurred at a rate of 7.9% for GG, 12.5% for AG and 55.6% for AA participants (p = 0.005). Multivariable models demonstrated A-carriers (versus GG) had 275.2 mL higher blood loss (95% CI 96.9-453.4, p < 0.01) controlling for parity, intrapartum oxytocin, self-reported ancestry, active management of third stage or genital tract lacerations. Furthermore, A-carrier individuals had a 79% higher risk for needing at least one second-line treatment (RR = 1.79, 95% CI = 1.08-2.95) controlling for covariates. Interaction models revealed that A-carriers who required no oxytocin for labor stimulation experienced 371.4 mL greater blood loss (95% CI 196.6-546.2 mL). We provide evidence of a risk allele in the oxytocin receptor gene that may be involved in the development of postpartum hemorrhage among participants undergoing vaginal birth, particularly among those with fewer risk factors. The findings, if reproducible, could be useful in studying pharmacogenomic strategies for predicting, preventing or treating postpartum hemorrhage. Abstract Background Postpartum hemorrhage remains a key contributor to overall maternal morbidity in the United States. Current clinical assessment methods used to predict postpartum hemorrhage are unable to prospectively identify about 40% of hemorrhage cases. Oxytocin is a first-line pharmaceutical for preventing and treating postpartum hemorrhage, which acts through oxytocin receptors on uterine myocytes. Existing research indicates that oxytocin function is subject to variation, influenced in part by differences in the DNA sequence within the oxytocin receptor gene. One variant, rs53576, has been shown to be associated with variable responses to exogenous oxytocin when administered during psychological research studies. How this variant may influence myometrial oxytocin response in the setting of third stage labor has not been studied. We tested for differences in the frequency of the oxytocin receptor genotype at rs53576 in relationship to the severity of blood loss among a sample of individuals who experienced vaginal birth. Methods A case–control prospective design was used to enroll 119 postpartum participants who underwent vaginal birth who were at least 37 weeks of gestation. Cases were defined by either a 1000 mL or greater blood loss or instances of heavier bleeding where parturients were given additional uterotonic treatment due to uterine atony. Controls were matched to cases on primiparity and labor induction status. Genotype was measured from a maternal blood sample obtained during the 2nd postpartum month from 95 participants. Statistical analysis included bivariate tests and generalized linear and Poisson regression modeling. Results The distribution of the genotype across the sample of 95 participants was 40% GG (n = 38), 50.5% AG (n = 48) and 9.5% AA (n = 9). Blood loss of 1000 mL or greater occurred at a rate of 7.9% for GG, 12.5% for AG and 55.6% for AA participants (p = 0.005). Multivariable models demonstrated A-carriers (versus GG) had 275.2 mL higher blood loss (95% CI 96.9–453.4, p < 0.01) controlling for parity, intrapartum oxytocin, self-reported ancestry, active management of third stage or genital tract lacerations. Furthermore, A-carrier individuals had a 79% higher risk for needing at least one second-line treatment (RR = 1.79, 95% CI = 1.08–2.95) controlling for covariates. Interaction models revealed that A-carriers who required no oxytocin for labor stimulation experienced 371.4 mL greater blood loss (95% CI 196.6–546.2 mL). Conclusions We provide evidence of a risk allele in the oxytocin receptor gene that may be involved in the development of postpartum hemorrhage among participants undergoing vaginal birth, particularly among those with fewer risk factors. The findings, if reproducible, could be useful in studying pharmacogenomic strategies for predicting, preventing or treating postpartum hemorrhage. Background Postpartum hemorrhage remains a key contributor to overall maternal morbidity in the United States. Current clinical assessment methods used to predict postpartum hemorrhage are unable to prospectively identify about 40% of hemorrhage cases. Oxytocin is a first-line pharmaceutical for preventing and treating postpartum hemorrhage, which acts through oxytocin receptors on uterine myocytes. Existing research indicates that oxytocin function is subject to variation, influenced in part by differences in the DNA sequence within the oxytocin receptor gene. One variant, rs53576, has been shown to be associated with variable responses to exogenous oxytocin when administered during psychological research studies. How this variant may influence myometrial oxytocin response in the setting of third stage labor has not been studied. We tested for differences in the frequency of the oxytocin receptor genotype at rs53576 in relationship to the severity of blood loss among a sample of individuals who experienced vaginal birth. Methods A case–control prospective design was used to enroll 119 postpartum participants who underwent vaginal birth who were at least 37 weeks of gestation. Cases were defined by either a 1000 mL or greater blood loss or instances of heavier bleeding where parturients were given additional uterotonic treatment due to uterine atony. Controls were matched to cases on primiparity and labor induction status. Genotype was measured from a maternal blood sample obtained during the 2 nd postpartum month from 95 participants. Statistical analysis included bivariate tests and generalized linear and Poisson regression modeling. Results The distribution of the genotype across the sample of 95 participants was 40% GG ( n = 38), 50.5% AG ( n = 48) and 9.5% AA ( n = 9). Blood loss of 1000 mL or greater occurred at a rate of 7.9% for GG, 12.5% for AG and 55.6% for AA participants ( p = 0.005). Multivariable models demonstrated A-carriers (versus GG) had 275.2 mL higher blood loss (95% CI 96.9–453.4, p < 0.01) controlling for parity, intrapartum oxytocin, self-reported ancestry, active management of third stage or genital tract lacerations. Furthermore, A-carrier individuals had a 79% higher risk for needing at least one second-line treatment (RR = 1.79, 95% CI = 1.08–2.95) controlling for covariates. Interaction models revealed that A-carriers who required no oxytocin for labor stimulation experienced 371.4 mL greater blood loss (95% CI 196.6–546.2 mL). Conclusions We provide evidence of a risk allele in the oxytocin receptor gene that may be involved in the development of postpartum hemorrhage among participants undergoing vaginal birth, particularly among those with fewer risk factors. The findings, if reproducible, could be useful in studying pharmacogenomic strategies for predicting, preventing or treating postpartum hemorrhage. |
| ArticleNumber | 884 |
| Author | Erickson, Elise N. Connelly, Jessica J. Perkeybile, Allison M. Myatt, Leslie Krol, Kathleen M. |
| Author_xml | – sequence: 1 givenname: Elise N. surname: Erickson fullname: Erickson, Elise N. email: eliseerickson@arizona.edu organization: University of Arizona, Oregon Health and Science University – sequence: 2 givenname: Kathleen M. surname: Krol fullname: Krol, Kathleen M. organization: University of Virginia – sequence: 3 givenname: Allison M. surname: Perkeybile fullname: Perkeybile, Allison M. organization: University of Virginia – sequence: 4 givenname: Jessica J. surname: Connelly fullname: Connelly, Jessica J. organization: University of Virginia – sequence: 5 givenname: Leslie surname: Myatt fullname: Myatt, Leslie organization: Oregon Health and Science University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36447139$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9Ustu1TAUtFARfcAPsECR2HQT8CNxnA0SqgpUqtQNXVaWY5_k-iqxg-1Q7t_j25TSdtGVH2dmzhx7jtGB8w4Qek_wJ0IE_xwJFaIqMaUlrimuy9tX6IhUDSkpa9nBo_0hOo5xizFpRI3foEPGq1xi7RG6ufqzS15bVwTQMCcfimjdMELhFj2CT9ZAMftxN_kwb2ycijmAsTrFQiXvdmWAUSUwGRPTrEJapmIDGRw2aoC36HWvxgjv7tcTdP3t_OfZj_Ly6vvF2dfLUnPcpJIwCgILpeqmN1pBW0E-ZbOcd4Zn15pUbc1pZYSpTCuIaaDDrAPT9Vjhnp2gi1XXeLWVc7CTCjvplZV3Fz4MMluzeSAJpieZJigzOLepFdGEKMWZMhVudZu1vqxa89JNYDS4FNT4RPRpxdmNHPxv2TaYt4RmgdN7geB_LRCTnGzUMI7KgV-ipE3FaswZ2_f6-Ay69Utw-akyqq4bRihlGfXhsaMHK_9-MQPoCtDBxxigf4AQLPdRkWtUZI6KvIuKvM0k8YykbVLJ-v1UdnyZylZqzH3cAOG_7RdYfwEUwNau |
| CitedBy_id | crossref_primary_10_1016_j_ajog_2023_04_011 crossref_primary_10_1186_s12884_025_07868_7 crossref_primary_10_1016_j_jogn_2023_11_003 crossref_primary_10_1016_j_ajogmf_2023_101089 crossref_primary_10_1016_j_outlook_2023_102059 crossref_primary_10_3390_ani13040768 crossref_primary_10_1007_s43032_024_01621_9 crossref_primary_10_1016_j_ajogmf_2023_101062 crossref_primary_10_1038_s41588_024_01839_y crossref_primary_10_1097_JPN_0000000000000935 crossref_primary_10_1080_14767058_2023_2239983 |
| Cites_doi | 10.1016/S0021-9258(18)31656-9 10.1097/AOG.0000000000004228 10.1097/SIH.0b013e318230604f 10.1016/j.ajog.2018.04.013 10.1186/s12881-019-0894-8 10.1177/089033449501100218 10.1016/j.ajog.2012.06.079 10.1097/AOG.0b013e3182941c78 10.1007/s00277-011-1381-2 10.1016/j.ogc.2015.01.014 10.1016/j.jpsychires.2014.08.021 10.1016/j.bpa.2022.02.002 10.1016/j.ajog.2020.01.026 10.3109/14767058.2014.937698 10.1016/j.jpsychires.2021.03.022 10.1111/jne.12154 10.1080/14767058.2016.1274302 10.1111/1471-0528.16040 10.1016/j.psyneuen.2016.09.018 10.1016/j.psyneuen.2014.01.012 10.1111/jmwh.12586 10.1097/GRF.0b013e3181cef930 10.1111/jmwh.12345 10.1016/j.ijoa.2021.103207 10.1016/j.psyneuen.2021.105268 10.1016/j.psyneuen.2021.105600 10.1016/j.ajog.2013.07.007 10.1016/j.biopsych.2015.08.008 10.1055/s-0040-1712166 10.1111/jmwh.13104 10.1016/j.jpsychires.2015.03.012 10.1213/01.ane.0000286233.48111.d8 10.1016/j.bpobgyn.2008.08.004 10.1097/AOG.0000000000001939 10.1093/scan/nsw150 10.1016/j.ajog.2018.04.052 10.1186/s12863-015-0323-8 10.1016/j.jogn.2020.08.005 10.1016/j.ajog.2010.08.023 10.1111/jmwh.12728 10.1007/s00277-011-1279-z 10.1016/j.ijoa.2020.07.008 10.1186/s12884-019-2365-9 10.1042/bj3150739 10.1111/gbb.12234 10.1016/j.ajog.2013.10.872 10.1016/j.jbi.2008.08.010 10.1111/jmwh.12556 10.1016/j.pnpbp.2019.109734 10.1111/aogs.14262 10.1002/erv.2354 10.1038/s41398-021-01546-w 10.1213/ANE.0000000000001268 10.1097/AOG.0000000000004579 10.1159/000508074 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022 2022. The Author(s). 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2022 – notice: 2022. The Author(s). – notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9- K9. KB0 M0R M0S M1P NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM DOA |
| DOI | 10.1186/s12884-022-05205-w |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) Consumer Health Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Consumer Health Database ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Family Health (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7RV name: Nursing & allied health premium. url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2393 |
| EndPage | 14 |
| ExternalDocumentID | oai_doaj_org_article_edf1dbf823d04e05a1c11aa63ad409c9 PMC9706912 36447139 10_1186_s12884_022_05205_w |
| Genre | Journal Article |
| GeographicLocations | Oregon United States--US |
| GeographicLocations_xml | – name: United States--US – name: Oregon |
| GrantInformation_xml | – fundername: Sigma Theta Tau International funderid: http://dx.doi.org/10.13039/100012400 – fundername: National Institutes of Health grantid: K12HD043488; R01HD098117; R01HD098117; R01HD098117; K12HD043488 funderid: http://dx.doi.org/10.13039/100000002 – fundername: NCATS NIH HHS grantid: UL1 TR002369 – fundername: NIH HHS grantid: K12HD043488 – fundername: NICHD NIH HHS grantid: K12 HD043488 – fundername: NIH HHS grantid: R01HD098117 – fundername: NICHD NIH HHS grantid: R01 HD098117 – fundername: ; – fundername: ; grantid: K12HD043488; R01HD098117; R01HD098117; R01HD098117; K12HD043488 |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5GY 5VS 6J9 6PF 7RV 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACUHS ADBBV ADRAZ ADUKV AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS AZQEC BAPOH BAWUL BCNDV BENPR BFQNJ BKNYI BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK IAO ICW IHR INH INR ITC K9- KQ8 M0R M1P M48 M~E N8Y NAPCQ O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ TR2 TUS UKHRP W2D WOQ WOW XSB ~8M AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK DWQXO K9. PKEHL PQEST PQUKI 7X8 5PM |
| ID | FETCH-LOGICAL-c607t-132e808aa57fdcae94e08a17866bd6017c1495624d8d4d981d7eb03bedbf0a0f3 |
| IEDL.DBID | BENPR |
| ISICitedReferencesCount | 13 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000890263000003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1471-2393 |
| IngestDate | Mon Nov 10 04:25:02 EST 2025 Tue Nov 04 02:07:29 EST 2025 Thu Sep 04 17:16:01 EDT 2025 Thu Oct 09 23:40:43 EDT 2025 Mon Jul 21 06:05:34 EDT 2025 Sat Nov 29 06:06:20 EST 2025 Tue Nov 18 21:26:06 EST 2025 Sat Sep 06 07:24:29 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Genetics Third stage labor Oxytocin receptor Postpartum hemorrhage Pharmacogenomics |
| Language | English |
| License | 2022. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c607t-132e808aa57fdcae94e08a17866bd6017c1495624d8d4d981d7eb03bedbf0a0f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/2755731223?pq-origsite=%requestingapplication% |
| PMID | 36447139 |
| PQID | 2755731223 |
| PQPubID | 44759 |
| PageCount | 14 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_edf1dbf823d04e05a1c11aa63ad409c9 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9706912 proquest_miscellaneous_2743506339 proquest_journals_2755731223 pubmed_primary_36447139 crossref_primary_10_1186_s12884_022_05205_w crossref_citationtrail_10_1186_s12884_022_05205_w springer_journals_10_1186_s12884_022_05205_w |
| PublicationCentury | 2000 |
| PublicationDate | 2022-11-29 |
| PublicationDateYYYYMMDD | 2022-11-29 |
| PublicationDate_xml | – month: 11 year: 2022 text: 2022-11-29 day: 29 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC pregnancy and childbirth |
| PublicationTitleAbbrev | BMC Pregnancy Childbirth |
| PublicationTitleAlternate | BMC Pregnancy Childbirth |
| PublicationYear | 2022 |
| Publisher | BioMed Central Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: Springer Nature B.V – name: BMC |
| References | HK Ahmadzia (5205_CR7) 2020; 18 N Buzaglo (5205_CR21) 2015; 28 EK Main (5205_CR27) 2020; 223 MN Schorn (5205_CR52) 2017; 62 5205_CR17 5205_CR18 C Feng (5205_CR44) 2015; 14 P Toledo (5205_CR50) 2012; 7 A Borovac-Pinheiro (5205_CR9) 2018; 219 PA Harris (5205_CR47) 2009; 42 M Vaht (5205_CR36) 2016; 74 EK Main (5205_CR8) 2015; 60 R Feldman (5205_CR33) 2016; 79 HB Ende (5205_CR24) 2021; 137 K Baek (5205_CR31) 1996; 315 CE Willis (5205_CR12) 1995; 11 J Kou (5205_CR42) 2020; 4 G Carroli (5205_CR26) 2008; 22 W Zhao (5205_CR43) 2020; 10 D Almeida (5205_CR56) 2022; 136 MS Kramer (5205_CR62) 2013; 209 RM Silver (5205_CR4) 2015; 42 N Milman (5205_CR10) 2011; 90 W Parry-Smith (5205_CR15) 2021; 137 5205_CR28 HB Ende (5205_CR19) 2021; 138 5205_CR22 5205_CR66 5205_CR23 5205_CR20 S Arrowsmith (5205_CR29) 2014; 26 K Schultebraucks (5205_CR41) 2021; 9 O Okunlola (5205_CR25) 2022; 14 5205_CR60 HT Sharp (5205_CR2) 2017; 129 H Ruppel (5205_CR63) 2021; 38 M Balki (5205_CR67) 2016; 122 N Akdemir (5205_CR57) 2020; 85 JA Kountanis (5205_CR14) 2020; 44 C Gyamfi-Bannerman (5205_CR16) 2018; 219 5205_CR37 5205_CR38 RM Silver (5205_CR6) 2010; 53 YR Kim (5205_CR35) 2015; 23 5205_CR39 5205_CR1 5205_CR34 M Heesen (5205_CR55) 2022; 36 L Ramo-Fernández (5205_CR58) 2021; 11 ME van Steijn (5205_CR13) 2020; 17 SA Hussain (5205_CR64) 2019; 11 MN Schorn (5205_CR51) 2016; 61 AM Barchi-Ferreira (5205_CR40) 2021; 129 AJ Dilla (5205_CR61) 2013; 122 PR Butovskaya (5205_CR54) 2016; 17 M Natrella (5205_CR48) 2018; 31 M Balki (5205_CR3) 2021; 48 P Toledo (5205_CR49) 2007; 105 M Widmer (5205_CR5) 2020; 127 5205_CR45 N Milman (5205_CR11) 2012; 91 5205_CR46 T Inoue (5205_CR30) 1994; 269 T Kimura (5205_CR32) 1995; 395 MN Schorn (5205_CR53) 2018; 63 F Füeg (5205_CR59) 2019; 20 CA Grotegut (5205_CR65) 2011; 204 |
| References_xml | – volume: 269 start-page: 32451 issue: 51 year: 1994 ident: 5205_CR30 publication-title: J Biol Chem doi: 10.1016/S0021-9258(18)31656-9 – volume: 137 start-page: 305 issue: 2 year: 2021 ident: 5205_CR24 publication-title: Obstet Gynecol doi: 10.1097/AOG.0000000000004228 – ident: 5205_CR34 – ident: 5205_CR1 – volume: 18 start-page: 247 issue: 4 year: 2020 ident: 5205_CR7 publication-title: Blood Transfus – volume: 7 start-page: 18 issue: 1 year: 2012 ident: 5205_CR50 publication-title: Simulation in healthcare : journal of the Society for Simulation in Healthcare doi: 10.1097/SIH.0b013e318230604f – volume: 11 start-page: e6456 issue: 12 year: 2019 ident: 5205_CR64 publication-title: Cureus – volume: 219 start-page: 162 issue: 2 year: 2018 ident: 5205_CR9 publication-title: Am J Obstet Gynecol doi: 10.1016/j.ajog.2018.04.013 – volume: 20 start-page: 178 issue: 1 year: 2019 ident: 5205_CR59 publication-title: BMC Med Genet doi: 10.1186/s12881-019-0894-8 – volume: 11 start-page: 123 issue: 2 year: 1995 ident: 5205_CR12 publication-title: J Hum Lact doi: 10.1177/089033449501100218 – ident: 5205_CR60 doi: 10.1016/j.ajog.2012.06.079 – volume: 122 start-page: 120 issue: 1 year: 2013 ident: 5205_CR61 publication-title: Obstet Gynecol doi: 10.1097/AOG.0b013e3182941c78 – volume: 91 start-page: 143 issue: 2 year: 2012 ident: 5205_CR11 publication-title: Ann Hematol doi: 10.1007/s00277-011-1381-2 – volume: 42 start-page: 381 issue: 2 year: 2015 ident: 5205_CR4 publication-title: Obstet Gynecol Clin North Am doi: 10.1016/j.ogc.2015.01.014 – ident: 5205_CR37 doi: 10.1016/j.jpsychires.2014.08.021 – volume: 36 start-page: 135 issue: 1 year: 2022 ident: 5205_CR55 publication-title: Best Pract Res Clin Anaesthesiol doi: 10.1016/j.bpa.2022.02.002 – volume: 223 start-page: 123.e1 issue: 1 year: 2020 ident: 5205_CR27 publication-title: Am J Obstet Gynecol doi: 10.1016/j.ajog.2020.01.026 – volume: 28 start-page: 932 issue: 8 year: 2015 ident: 5205_CR21 publication-title: J Matern Fetal Neonatal Med doi: 10.3109/14767058.2014.937698 – volume: 9 start-page: 1 year: 2021 ident: 5205_CR41 publication-title: Neuropsychopharmacol – volume: 395 start-page: 259 year: 1995 ident: 5205_CR32 publication-title: Adv Exp Med Biol – volume: 137 start-page: 419 year: 2021 ident: 5205_CR15 publication-title: J Psychiatr Res doi: 10.1016/j.jpsychires.2021.03.022 – volume: 26 start-page: 356 issue: 6 year: 2014 ident: 5205_CR29 publication-title: J Neuroendocrinol doi: 10.1111/jne.12154 – volume: 31 start-page: 106 issue: 1 year: 2018 ident: 5205_CR48 publication-title: J Matern Fetal Neonatal Med doi: 10.1080/14767058.2016.1274302 – volume: 127 start-page: 628 issue: 5 year: 2020 ident: 5205_CR5 publication-title: BJOG doi: 10.1111/1471-0528.16040 – volume: 74 start-page: 333 year: 2016 ident: 5205_CR36 publication-title: Psychoneuroendocrinology doi: 10.1016/j.psyneuen.2016.09.018 – ident: 5205_CR38 doi: 10.1016/j.psyneuen.2014.01.012 – volume: 62 start-page: 58 issue: 1 year: 2017 ident: 5205_CR52 publication-title: Journal of Midwifery & Womens Health doi: 10.1111/jmwh.12586 – volume: 53 start-page: 252 issue: 1 year: 2010 ident: 5205_CR6 publication-title: Clin Obstet Gynecol doi: 10.1097/GRF.0b013e3181cef930 – volume: 60 start-page: 458 issue: 4 year: 2015 ident: 5205_CR8 publication-title: Journal of Midwifery and Women’s Health doi: 10.1111/jmwh.12345 – volume: 48 start-page: 103207 year: 2021 ident: 5205_CR3 publication-title: Int J Obstet Anesth doi: 10.1016/j.ijoa.2021.103207 – volume: 14 start-page: e26460 issue: 6 year: 2022 ident: 5205_CR25 publication-title: Cureus – ident: 5205_CR17 – volume: 4 start-page: 1 year: 2020 ident: 5205_CR42 publication-title: Psychol Med – volume: 129 start-page: 105268 year: 2021 ident: 5205_CR40 publication-title: Psychoneuroendocrinology doi: 10.1016/j.psyneuen.2021.105268 – volume: 136 start-page: 105600 year: 2022 ident: 5205_CR56 publication-title: Psychoneuroendocrinology doi: 10.1016/j.psyneuen.2021.105600 – volume: 209 start-page: 449.e1 issue: 5 year: 2013 ident: 5205_CR62 publication-title: Am J Obstet Gynecol doi: 10.1016/j.ajog.2013.07.007 – volume: 79 start-page: 174 issue: 3 year: 2016 ident: 5205_CR33 publication-title: Biol Psychiat doi: 10.1016/j.biopsych.2015.08.008 – volume: 38 start-page: 1192 issue: 11 year: 2021 ident: 5205_CR63 publication-title: Am J Perinatol doi: 10.1055/s-0040-1712166 – ident: 5205_CR23 doi: 10.1111/jmwh.13104 – ident: 5205_CR39 doi: 10.1016/j.jpsychires.2015.03.012 – volume: 105 start-page: 1736 issue: 6 year: 2007 ident: 5205_CR49 publication-title: Anesth Analg doi: 10.1213/01.ane.0000286233.48111.d8 – volume: 22 start-page: 999 issue: 6 year: 2008 ident: 5205_CR26 publication-title: Best Pract Res Clin Obstet Gynaecol doi: 10.1016/j.bpobgyn.2008.08.004 – ident: 5205_CR46 – volume: 129 start-page: 603 issue: 4 year: 2017 ident: 5205_CR2 publication-title: Obstet Gynecol doi: 10.1097/AOG.0000000000001939 – ident: 5205_CR45 doi: 10.1093/scan/nsw150 – volume: 219 start-page: 185.e1 issue: 2 year: 2018 ident: 5205_CR16 publication-title: Am J Obstet Gynecol doi: 10.1016/j.ajog.2018.04.052 – volume: 17 start-page: 17 issue: 1 year: 2016 ident: 5205_CR54 publication-title: BMC Genet doi: 10.1186/s12863-015-0323-8 – ident: 5205_CR66 doi: 10.1016/j.jogn.2020.08.005 – volume: 204 start-page: 56.e1 issue: 1 year: 2011 ident: 5205_CR65 publication-title: Am J Obstet Gynecol doi: 10.1016/j.ajog.2010.08.023 – volume: 63 start-page: 446 issue: 4 year: 2018 ident: 5205_CR53 publication-title: Journal of Midwifery and Women’s Health doi: 10.1111/jmwh.12728 – volume: 90 start-page: 1247 issue: 11 year: 2011 ident: 5205_CR10 publication-title: Ann Hematol doi: 10.1007/s00277-011-1279-z – volume: 44 start-page: 90 year: 2020 ident: 5205_CR14 publication-title: Int J Obstet Anesth doi: 10.1016/j.ijoa.2020.07.008 – ident: 5205_CR28 doi: 10.1186/s12884-019-2365-9 – volume: 315 start-page: 739 issue: Pt 3 year: 1996 ident: 5205_CR31 publication-title: Biochem J doi: 10.1042/bj3150739 – volume: 14 start-page: 516 issue: 7 year: 2015 ident: 5205_CR44 publication-title: Genes Brain Behav doi: 10.1111/gbb.12234 – volume: 17 start-page: 1 year: 2020 ident: 5205_CR13 publication-title: J Psychosom Obstet Gynaecol – ident: 5205_CR20 doi: 10.1016/j.ajog.2013.10.872 – volume: 42 start-page: 377 issue: 2 year: 2009 ident: 5205_CR47 publication-title: J Biomed Inform doi: 10.1016/j.jbi.2008.08.010 – volume: 61 start-page: 662 issue: 5 year: 2016 ident: 5205_CR51 publication-title: Journal of Midwifery & Womens Health doi: 10.1111/jmwh.12556 – ident: 5205_CR18 – volume: 10 start-page: 109734 issue: 96 year: 2020 ident: 5205_CR43 publication-title: Prog Neuropsychopharmacol Biol Psychiatry doi: 10.1016/j.pnpbp.2019.109734 – ident: 5205_CR22 doi: 10.1111/aogs.14262 – volume: 23 start-page: 171 issue: 3 year: 2015 ident: 5205_CR35 publication-title: European eating disorders review : the journal of the Eating Disorders Association doi: 10.1002/erv.2354 – volume: 11 start-page: 449 issue: 1 year: 2021 ident: 5205_CR58 publication-title: Transl Psychiatry doi: 10.1038/s41398-021-01546-w – volume: 122 start-page: 1508 issue: 5 year: 2016 ident: 5205_CR67 publication-title: Anesth Analg doi: 10.1213/ANE.0000000000001268 – volume: 138 start-page: 924 issue: 6 year: 2021 ident: 5205_CR19 publication-title: Obstet Gynecol doi: 10.1097/AOG.0000000000004579 – volume: 85 start-page: 343 issue: 4 year: 2020 ident: 5205_CR57 publication-title: Gynecol Obstet Invest doi: 10.1159/000508074 |
| SSID | ssj0017850 |
| Score | 2.3916829 |
| Snippet | Background
Postpartum hemorrhage remains a key contributor to overall maternal morbidity in the United States. Current clinical assessment methods used to... Postpartum hemorrhage remains a key contributor to overall maternal morbidity in the United States. Current clinical assessment methods used to predict... Background Postpartum hemorrhage remains a key contributor to overall maternal morbidity in the United States. Current clinical assessment methods used to... Abstract Background Postpartum hemorrhage remains a key contributor to overall maternal morbidity in the United States. Current clinical assessment methods... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 884 |
| SubjectTerms | African Americans Births Blood transfusions Case-Control Studies Childbirth & labor Female Gene expression Genealogy Genetics Genotype Gynecology Hemorrhage Humans Induced labor Maternal and Child Health Medicine Medicine & Public Health Morbidity Oxytocin - genetics Oxytocin - therapeutic use Oxytocin receptor Pharmacogenomics Placenta Polymorphism, Single Nucleotide Postpartum hemorrhage Postpartum Hemorrhage - genetics Pregnancy Prospective Studies Receptors, Oxytocin - genetics Reproductive Medicine Risk factors Third stage labor Uterine Inertia - genetics Vagina |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQhRAXxJvQgozEDaz6Fds5AqLiQuEAUi_IcmxHu9I2G22ylP77jp1kYXleuMZOZH0ztr8vHs8g9FwIqZhvAgG2GogUEtZB2EZIGVNt61pST0MuNqFPT83ZWfXxh1JfKSZsTA88AnccQ8NC3RguApWRlo55xpxTwgWQJj5f3QPWM4up6fxAm5LOV2SMOu5hFTaSpMj1FPdRkou9bShn6_8dxfw1UvKn49K8C53cRrcm-ohfjcO-g67F9i668X46IL-Hvnz4djkA3i2GlSx2IKhx-hmwirhNiYvXwzJE3K1XoPgB4GV_jrtNennoMajv9pLkuy0xQJ9-6ACd7TlepGDczQIWnvvo88nbT2_ekamCAvGK6lRnnkdDjXOlboJ3sQIEjQN0lKoDSDHts0DiMpggQwXcVceaijoC4tTRRjxAB-26jY8QbmBXCwC4E9JLxevKqSpqZ2rWAEPjTYHYDKj1U3rxVOViZbPMMMqORrBgBJuNYC8K9GL3Tjcm1_hr79fJTrueKTF2fgDuYid3sf9ylwIdzVa202ztLddlqQUDplSgZ7tmmGfp8MS1cb1NfYBYAp8T8ImHo1PsRiKAVILYhxa95y57Q91vaZeLnMu70lRVjBfo5exY34f1Zyge_w8oDtFNnmYEY4RXR-hg2GzjE3Tdfx2W_eZpnk9X8Ycmdg priority: 102 providerName: Directory of Open Access Journals – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3LjtMw0IIFIS68H4EFGYkbRNixYztHQKy4sCBe2guyHNuhldokSlKW_j1jNwkqLEhwTD2OpuN5ZsYzCD1mjAtqK5eCt-pSzjjoQTAjae7DbOuSE0tcHDYhj4_VyUnxbrwU1k_V7lNKMmrqKNZKPOtBkyqehurzULuRp6fn0QUwdyqI4_sPn-fcgVQ5ma7HnLlvzwTFTv1nuZe_V0n-kiqNFujo6v_hfg1dGT1O_HzHItfROV_fQJfejDn1m-jL2-_bAY6oxqD8fAsxOA7fD1Ye16HXcTMsncdts9quGziTZb_GbRc2Dz2GgL3epvE6jHcA0w8tcOJmjRehfrdbgK66hT4dvfr48nU6Dl1IrSAyjKbPvCLKmFxWzhpfcA9PQFQhSgfRm7Qxpsq4U447oL6TviSs9K6siCEVu40O6qb2dxGuwBA6UljDuOUiKwsjCi-NKmkFTl1WJYhO56Dt2JE8DMZY6RiZKKF3dNNANx3ppk8T9GTe0-76cfwV-kU43hky9NKOPzTdVz2KpvauooC8ypgj8GdzQy2lxghmHAS_tkjQ4cQcehTwXmcyzyWj4Fwl6NG8DKIZ8i2m9s0mwIAvCi4gg1fc2fHSjAkDP1TSsCL3uGwP1f2VermI7b8LSURBswQ9nXjtJ1p_JsW9fwO_jy5ngV0pTbPiEB0M3cY_QBftt2HZdw-jwP0A_tMqXg priority: 102 providerName: Springer Nature |
| Title | Oxytocin receptor single nucleotide polymorphism predicts atony-related postpartum hemorrhage |
| URI | https://link.springer.com/article/10.1186/s12884-022-05205-w https://www.ncbi.nlm.nih.gov/pubmed/36447139 https://www.proquest.com/docview/2755731223 https://www.proquest.com/docview/2743506339 https://pubmed.ncbi.nlm.nih.gov/PMC9706912 https://doaj.org/article/edf1dbf823d04e05a1c11aa63ad409c9 |
| Volume | 22 |
| WOSCitedRecordID | wos000890263000003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: Open Access: BioMedCentral Open Access Titles customDbUrl: eissn: 1471-2393 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017850 issn: 1471-2393 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1471-2393 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017850 issn: 1471-2393 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1471-2393 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017850 issn: 1471-2393 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Consumer Health Database (ProQuest) customDbUrl: eissn: 1471-2393 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017850 issn: 1471-2393 databaseCode: M0R dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1471-2393 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017850 issn: 1471-2393 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & allied health premium. customDbUrl: eissn: 1471-2393 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017850 issn: 1471-2393 databaseCode: 7RV dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1471-2393 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017850 issn: 1471-2393 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1471-2393 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017850 issn: 1471-2393 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1471-2393 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017850 issn: 1471-2393 databaseCode: RSV dateStart: 20011201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR1Nb9Mw1GItQlz4hhVGFSRuEM2Ondg5IYY2waGlKjCVA4oc26GV2iRrUkb_Pc9ukql87MLFSmInsvO-_Z7fQ-glpSwiKtM-aKvaZ5QBHwQx4ofG1rZOGVZYu2ITfDwWs1k8aTbcqiassuWJjlHrQtk98uOAhyGnBKTZm_LCt1WjrHe1KaFxgPo2Uxnrof7J6Xgy7fwIXIS4PSojouMKuLFgvo1gt_EfoX-5J45c1v6_qZp_Rkz-5jZ10ujs7v-u4x660-ih3tsd4txHN0z-AN0aNZ72h-jbx5_bGgCXe8ASTQmWuWd3FZbGy20G5KJeaOOVxXK7KgBSi2rllWv7cl15YMbnW98dkjEaxlR1Cfi5WXlzG9W7ngMHe4S-nJ1-fvfeb0ox-CrC3BasD4zAQsqQZ1pJEzMDd_B7oyjVYNNx5SytgGmhmY5BCeYmxTQ1Os2wxBl9jHp5kZtD5GUgHjWOlaRMsShIYxnFhkuRkgxUvSAbINJCJFFNnnJbLmOZOHtFRMkOiglAMXFQTC4H6FX3TrnL0nHt6BML6G6kzbDtHhTr70lDsInRGYHJi4BqDIsNJVGESBlRqcEkVvEAHbXwTRqyr5Ir4A7Qi64bCNZ6YWRuio0dAxoqKIYUPvFkh1XdTChop5zYHr6Hb3tT3e_JF3OXFDzmOIpJMECvW8y8mta_f8XT61fxDN0OLLEQ4gfxEerV6415jm6qH_WiWg_RAZ-e23bGXSuGDfkN3c4GtCMM1_3Jh9HkK9xNP53_AgbdPEc |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELZKQcCF92OhQJDgBFH9SGLngBCvqlUfIFSqXpBxbIddaTcJSZZl_xS_kbE32Wp59NYDx8ROZCfffDNjj2cQesJYlBCdmxCsVRNGLAIeBDUSxtbVts4irLHxxSb4wYE4Pk4_rKGf_VkYF1bZc6InalNqt0a-SXkcc0ZAm72svoWuapTbXe1LaCxgsWvnM3DZmhc7b-H_PqV0693hm-2wqyoQ6gRzV3udWoGFUjHPjVY2jSxcES6SJDPgnnDtnQYaGWEik4I9x22GWWZNlmOFcwbvPYfOA48TF0LGPx4tdy24iHF_MEckmw1wv4hCFy_vok3icLai_HyNgL8Ztn_GZ_62Set139bV_-2rXUNXOis7eLUQi-tozRY30MX9Lo7gJvr8_se8BVgWARC-rdqyDtyaydgGhcvvXLYjY4OqHM8nJeBw1EyCqnYPt02gwFieh_4IkDXQp2krkL7pJBi6mOV6CPx8C306k8ndRutFWdi7KMhB-RucasUiHSU0S1WSWq5ERnIwZGk-QKRHgNRdFnZXDGQsvTcmErlAjQTUSI8aORugZ8tnqkUOklN7v3bAWvZ0-cP9jbL-Kjs6ktbkBAYvKDMYJhsroglRKmHKgMOv0wHa6PEkO1Jr5AmYBujxshnoyO0xqcKWU9cH7G8wexm84s4CxcuRMLC9OXEtfAXfK0NdbSlGQ5_yPOU4SQkdoOe9JJwM69-f4t7ps3iELm0f7u_JvZ2D3fvoMnWCSkhI0w203tZT-wBd0N_bUVM_9GIeoC9nLSG_AKEBkUs |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Zj9QwDI5gQSteuI_CAkXiDapNmrRJH7lGIGBYiUP7gqI0SZmRZtqq7bDMv8dJDxhYkBCPbZwqcezkc-3YCD2klKVEFyYCtGoiRhnsg3CMRIl1ta1zhjU2vtgEn8_F8XF29NMtfh_tProk-zsNLktT2R3WpuhVXKSHLeyqgkUuEt3FcSTRyVl0jrmiQc5ef_9p8iNwkeDxqsyp_XaOI5-1_zSo-XvE5C9uU38azS79_zwuo4sDEg2f9KJzBZ2x5VW0_3bwtV9Dn99923awdGUIm6KtwTYP3X-FlQ1LlwO56pbGhnW12q4rWKtluw7rxnXu2hAM-XIb-Wsy1gBN29UgoZt1uHBxvc0C9rDr6OPsxYdnL6OhGEOkU8xdyfrYCiyUSnhhtLIZs_AEDE7T3IBVx7W3tWJmhGEmAxjMbY5pbk1eYIULegPtlVVpb6GwgAPS4EwryjRL4zxTaWa5EjkpAOzFRYDIuCZSD5nKXcGMlfQWi0hlzzcJfJOeb_IkQI-mPnWfp-Ov1E_dUk-ULse2f1E1X-SgstKagsDgRUwNhskmimhClEqpMmAU6yxAB6OgyEHxWxnzJOGUAOgK0IOpGVTW-WFUaauNowGMCtCQwidu9nI1jYQCPuXEtfAdidsZ6m5LuVz4tOAZx2lG4gA9HuXux7D-zIrb_0Z-H-0fPZ_JN6_mr--gC7GTXEKiODtAe12zsXfRef21W7bNPa-H3wHN9zYm |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Oxytocin+receptor+single+nucleotide+polymorphism+predicts+atony-related+postpartum+hemorrhage&rft.jtitle=BMC+pregnancy+and+childbirth&rft.au=Erickson%2C+Elise+N&rft.au=Krol%2C+Kathleen+M&rft.au=Perkeybile%2C+Allison+M&rft.au=Connelly%2C+Jessica+J&rft.date=2022-11-29&rft.eissn=1471-2393&rft.volume=22&rft.issue=1&rft.spage=884&rft_id=info:doi/10.1186%2Fs12884-022-05205-w&rft_id=info%3Apmid%2F36447139&rft.externalDocID=36447139 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2393&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2393&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2393&client=summon |